SiteOne Therapeutics Secures Major Financing to Advance Pain Treatments
SiteOne Therapeutics, Inc., a pioneering biopharmaceutical company focused on developing selective ion channel modulators for treating pain and related conditions, has successfully completed a $100 million Series C financing round. This significant funding was led by Novo Holdings, accompanied by notable participation from OrbiMed, Wellington Management, Mission BioCapital, BSQUARED Capital, and existing investors. The capital raised will greatly enhance SiteOne's capabilities to advance its innovative portfolio of selective, small molecule ion channel modulators aimed at addressing sensory hyperexcitability disorders through critical human clinical validation.
Appointment of Experienced Board Members
In alignment with the financing, SiteOne Therapeutics has strengthened its leadership team by appointing several esteemed figures to its Board of Directors. Among the new members are Ken Harrison, Ph.D., Senior Partner at Novo Holdings, Mona Ashiya, Ph.D., Partner at OrbiMed, and Zach Collins, Ph.D., Partner at Mission BioCapital. Additionally, the company welcomes Praveen Tipirneni, M.D., previously CEO of Morphic Therapeutic, as the Executive Chairperson and Martin Edwards, M.D., known for his extensive expertise in life sciences, as an independent Board member.
Innovation in Non-opioid Pain Relief
SiteOne Therapeutics is dedicated to the mission of creating non-opioid solutions for disorders that involve hyperexcitability of the peripheral nervous system, including pain and cough. Their strategic approach centers around the action potential—the basic element of electrical signaling within the peripheral nervous system. This funding empowers the undertaking of human proof of concept studies for their isoform-selective sodium channel inhibitors, with development plans extending to other ion channel modulators. John Mulcahy, Ph.D., the President and CEO of SiteOne, expressed optimism saying, "This funding will allow us to further our mission, aided by the expertise of our esteemed new Board members in areas crucial for drug development and business strategies.”
Advancements in Ion Channel Modulators
SiteOne is at the forefront of developing selective, best-in-class sodium channel inhibitors, particularly targeting the NaV1.7 and NaV1.8 channels. The company’s leading program for pain management focuses on the NaV1.8 channel, which is primarily found in the peripheral nervous system. This innovative approach promises to deliver significant analgesic effects while mitigating the side effect profiles and abuse risks associated with existing treatments that primarily target the central nervous system. Additionally, SiteOne is exploring various sodium channels and other validated targets for treating sensory hyperexcitability disorders.
Support and Confidence from Industry Leaders
Ken Harrison from Novo Holdings remarked on the potential of SiteOne’s selective ion channel modulators, stating, "The innovative approach taken by SiteOne Therapeutics could change the landscape of pain management for chronic pain sufferers, as they are rooted in substantial scientific exploration regarding ion channels’ roles in peripheral nerve excitability.”
Praveen Tipirneni emphasized the company’s strategic focus, stating, “While many firms lean towards central nervous system therapies, SiteOne is harnessing the power of peripheral nerve targeting to create effective treatments for pain and sensory hyperexcitability disorders without the adverse central-mediated effects.” Tipirneni expressed excitement about contributing to SiteOne’s mission in developing valuable therapeutic options for patients worldwide.
About Novo Holdings
Founded to manage the assets and wealth of the Novo Nordisk Foundation, Novo Holdings invests strategically to enhance global health and sustainability. The company aims to create long-term financial returns while addressing societal health needs. With a robust portfolio that includes equities, bonds, private equity, and properties, Novo Holdings has become a leader in life sciences investments, supporting innovative firms across all stages of development.
About SiteOne Therapeutics
SiteOne Therapeutics is committed to advancing a novel class of highly selective small molecule inhibitors designed to target NaV1.7, NaV1.8, and other relevant voltage-gated ion channels. These advancements aim to tackle sensory hyperexcitability disorders like chronic cough, itch, and pain. From its inception, SiteOne has focused on creating safe and effective pain-relief therapies that minimize addiction risks and side effects often associated with opioids. The firm is also developing unique drug candidates exhibiting precision in targeting specific ion channel subtypes for additional sensory conditions.
Frequently Asked Questions
What is the recently announced financing amount for SiteOne Therapeutics?
SiteOne Therapeutics announced a successful $100 million Series C financing to enhance its research and development activities.
Who are the new members of SiteOne Therapeutics' Board of Directors?
Ken Harrison, Mona Ashiya, Zach Collins, Martin Edwards, and Praveen Tipirneni have joined as new board members to provide strategic guidance.
What conditions are being targeted by SiteOne Therapeutics' treatments?
SiteOne is focusing on conditions involving hyperexcitability of the peripheral nervous system, particularly pain and cough.
What is the significance of the NaV1.8 channel in SiteOne's research?
The NaV1.8 channel is predominantly found in the peripheral nervous system and is central to SiteOne's approach to providing effective pain relief.
What is the mission of SiteOne Therapeutics?
SiteOne aims to develop non-opioid therapies for chronic pain sufferers, minimizing addiction potential while maximizing therapeutic benefits.
